Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zubsolv sublingual tablets Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction & Methadone & Buprenorphine

NCT02045693
View directory record Official record
Conditions
Hepatitis C
Interventions
Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 23, 2026, 8:54 PM EDT
Not yet recruiting Phase 4 Interventional

A Bundled Intervention to End Opioid Overdoses

NCT07485335
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
Bundled intervention (Experimental), control group, Buprenorphine (Experimental), Scheduled Peer Support Specialist (Experimental), Telemedicine Buprenorphine Treatment
Other · Drug · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 23, 2026, 8:54 PM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

NCT00552578
View directory record Official record
Conditions
Opiate Addiction, Refractory Pain
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Sep 23, 2026, 8:54 PM EDT
Terminated Phase 3 Interventional

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

NCT00768482
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant), Sublingual Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

NCT03604159
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 4 Interventional Results available

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

NCT02038790
View directory record Official record
Conditions
Opioid Dependence
Interventions
Suboxone Sublingual Film, Zubsolv sublingual tablets
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 2 Interventional Results available

Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse

NCT01967641
View directory record Official record
Conditions
Opioid Dependence
Interventions
buprenorphine/naloxone combination
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 4 Interventional Results available

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

NCT01903005
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
Higher bioavailability BNX sublingual tablets
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Jefferson County, Alabama • Marion County, Alabama • Winston County, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

NCT01846455
View directory record Official record
Conditions
Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions
2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Medications Development for Drug Abuse Disorders

NCT01188421
View directory record Official record
Conditions
Opioid Related Disorders, Opioid Dependence, Opioid Addiction
Interventions
Buprenorphine/naloxone, Clonidine, Tramadol ER
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 23, 2026, 8:54 PM EDT
Withdrawn Phase 4 Interventional

Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder

NCT04234516
View directory record Official record
Conditions
Opioid-use Disorder, Suicidal Ideation
Interventions
Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film, Morphine Sulfate 30 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 23, 2026, 8:54 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Not applicable Interventional Results available

HIV, Buprenorphine, and the Criminal Justice System

NCT01550341
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
Buprenorphine/naloxone, Placebo Oral Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT03766893
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 23, 2026, 8:54 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 23, 2026, 8:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine HCl/Naloxone HCl
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 1Phase 2 Interventional

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

NCT00000320
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine formulation: liquid vs. tablet
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-6000

NCT03002961
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, Suboxone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 23, 2026, 8:54 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT04139213
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
buprenorphine/naloxone oral product, injectable naltrexone, Pharmacy maintenance addiction care, oral naltrexone
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 23, 2026, 8:54 PM EDT